Christopher Senner – Exelixis Inc

Christopher Senner

Public – Medium Company

Christopher (“Chris”) J. Senner serves as Exelixis’s Executive Vice President and Chief Financial Officer, a position he has held since July 2015. He exercises strategic oversight of the company’s global finance function in this capacity, demonstrating adept stewardship of assets to fortify the financial framework supporting Exelixis’ dynamic expansion. Through his leadership, he facilitates allocating resources to bolster the advancement of Exelixis’ proprietary and collaborative endeavors and initiate pioneering clinical development initiatives. He is known for his strategic vision and collaborative approach, fostering partnerships and initiatives that advance the development of life-saving therapies for patients worldwide.

Mr. Senner has played a critical role in Exelixis’ transformation into a global, multi-product oncology company, including involvement in significant commercial product launches over the years (as noted under Significant Actions/Developments). Mr. Senner takes a fair and equitable approach to leading Finance, taking his role in allocating capital and doing what’s best for the company and its key stakeholders very seriously. Beyond his tangible success and expertise in the finance arena, Mr. Senner is known for having intangible solid leadership skills, including “followership,” as noted by those who work closely with him. 

Before assuming his role at Exelixis, Mr. Senner distinguished himself as the Vice President of Corporate Finance at Gilead Sciences, a leading research-driven biopharmaceutical company specializing in discovering, developing, and commercializing innovative medicines. Mr. Senner was with Gilead Sciences for over five years. During that time, he demonstrated exceptional financial acumen and leadership and directed critical facets of financial management, encompassing controllership, tax strategy, treasury operations, and corporate and operational financial planning. 

Before his tenure at Gilead Sciences, Mr. Senner amassed an extensive eighteen-year tenure at Wyeth Pharmaceuticals, where he occupied various pivotal financial positions, most notably his appointment as Chief Financial Officer of the U.S. region in 2007. His tenure at Wyeth Pharmaceuticals underscored his proficiency in navigating diverse financial landscapes and contributing significantly to organizational success.

In addition to his corporate leadership roles, Mr. Senner has extended his expertise to corporate governance, serving as a member of the Board of Directors for Quince Therapeutics since 2019. Mr. Senner is a Bentley University graduate with a degree in Finance.